Skip to main content


Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Priming with Toll-like receptor 3 agonist or interferon-gamma enhances the therapeutic effects of human mesenchymal stem cells in a murine model of atopic dermatitis

Fig. 3

Primed Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) elicit enhanced therapeutic effects in mice with Aspergillus fumigatus (Af)-induced atopic dermatitis (AD). a Mice were subcutaneously injected with WJ-MSCs primed with poly I:C or interferon-gamma (IFN-γ) on the final day of Af application and sacrificed on day 29 for further analyses. Clinical symptom scores (left) and transepidermal water loss (TEWL) were determined. b Histopathologic features of skin. Staining with haematoxylin-eosin (top) and toluidine blue (bottom). c Epidermal and dermal thickness was measured. Data are presented as the mean ± SEM (N = 6 per group). **, p < 0.005; ***, p < 0.0005 compared with the control group; #, p < 0.05 compared with the AD group; †, p < 0.05; ††, p < 0.005 compared with the group injected with non-primed WJ-MSCs. Scale bar = 100 μm

Back to article page